Management of Elevated Triglycerides

Assessment and Treatment

For a patient with dyslipidemia on rosuvastatin 20mg with triglyceride levels of 289 mg/dL, adding fenofibrate therapy is reasonable to target the residual hypertriglyceridemia, as the triglyceride level falls into the moderate hypertriglyceridemia range (200-499 mg/dL), which warrants consideration of additional therapy beyond statins 1
The American Heart Association recommends a triglyceride goal of <150 mg/dL, and the patient's level of 289 mg/dL significantly exceeds this target, indicating the need for additional therapy 1
Fibrates, such as fenofibrate, are considered the most potent triglyceride-lowering agents, capable of reducing triglycerides by up to 50% 1

The American Heart Association recommends reduced intake of saturated fats (<7% of total calories), limited dietary cholesterol (<200 mg/day), minimized trans fat intake (<1% of energy), promoting daily physical activity and weight management, and restriction of simple sugar and alcohol intake to help manage triglyceride levels 2, 1
The combination of statin and fenofibrate requires monitoring for potential myopathy, but the risk is lower with fenofibrate compared to other fibrates 3, 2

Despite improvements in lipid parameters, clinical outcome trials with fenofibrate have not consistently demonstrated reductions in cardiovascular events, highlighting the need for careful patient selection and monitoring 1
Monitor for muscle symptoms and obtain baseline and follow-up CPK levels when combining statin and fenofibrate to minimize the risk of myopathy 3, 2

The American College of Cardiology recommends treatment for moderate hypertriglyceridemia, defined as triglyceride levels between 200-499 mg/dL, which is the range for the patient in question with a triglyceride level of 273 mg/dL 4
The American College of Cardiology suggests evaluating renal function, including serum creatinine and eGFR, before starting fenofibrate, within 3 months after initiation, and every 6 months thereafter, with dose adjustments based on eGFR levels 5, 6

The American College of Cardiology guidelines indicate that if eGFR is between 30-59 mL/min/1.73 m², the dose of fenofibrate should not exceed 54 mg/day, and fenofibrate should not be used if eGFR is <30 mL/min/1.73 m² 5, 6
Fenofibrate has a better safety profile than gemfibrozil when combined with statins, as noted by the American College of Cardiology, if future combination therapy is needed 5

The American College of Cardiology recommends initiating fenofibrate 54-160 mg daily immediately as first-line therapy to prevent acute pancreatitis in patients with severe hypertriglyceridemia (≥500 mg/dL), regardless of LDL-C levels or cardiovascular risk 7
The American College of Cardiology suggests that statins are first-line pharmacologic therapy for moderate hypertriglyceridemia (200-499 mg/dL) if the patient has elevated LDL-C or 10-year ASCVD risk ≥7.5%, providing 10-30% dose-dependent triglyceride reduction and proven cardiovascular benefit 7

The American College of Cardiology recommends using lower statin doses (e.g., atorvastatin 10-20 mg maximum) when combining fenofibrate with statins to minimize myopathy risk, particularly in patients >65 years or with renal disease 7
Combination therapy with statin plus fibrate has not been shown to improve cardiovascular outcomes in major trials (ACCORD, FIELD), according to the American College of Cardiology 7, 8

The American College of Cardiology advises against using fenofibrate as first-line therapy for moderate hypertriglyceridemia when statins are indicated, as statins provide proven cardiovascular benefit while fenofibrate does not 7, 8
Fenofibrate was associated with less albuminuria progression and less retinopathy requiring laser treatment in the FIELD study, prompting some use for prevention of microvascular complications in patients with type 2 diabetes and elevated triglycerides, according to the American College of Cardiology 7, 8

The American Journal of Kidney Diseases recommends that fenofibrate must not be used in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) 9
The European Heart Journal states that the risk of myopathy and rhabdomyolysis is significantly increased when fenofibrate is combined with statins, particularly in high-risk populations, including elderly patients, those with diabetes mellitus, renal failure, and hypothyroidism 10, 11
The European Heart Journal recommends that fenofibrate has a better safety profile than gemfibrozil when combined with statins because it does not interfere with statin glucuronidation 12
The American Journal of Kidney Diseases notes that fibrate use was associated with acute reduction in eGFR and increased risk of hospitalization for elevated creatinine 9
The European Heart Journal advises that statin plus fibrate combination therapy has not been shown to improve cardiovascular outcomes and is generally not recommended 11
The Diabetes Care journal suggests that men with triglycerides ≥204 mg/dL AND HDL ≤34 mg/dL may show possible benefit in ACCORD subgroup analysis 11
The European Heart Journal warns that long-term statin therapy carries a possible risk of type 2 diabetes, but the cardiovascular benefits far outweigh this risk for the vast majority of patients 10

The European Heart Journal recommends taking fibrates in the morning and statins in the evening to minimize peak dose concentrations 10
The European Heart Journal and Diabetes Care journal advise against combining statins with gemfibrozil, and instead recommend using fenofibrate if combination therapy is necessary 10, 11